Hyderabad: Vivint Pharma, a leading injectables pharmaceutical company, has announced a significant investment of Rs 400 crore to establish a state-of-the-art injectables manufacturing facility in Genome Valley.
Vivint Pharma, a leading injectables pharmaceutical company, has announced a significant investment of Rs 400 crore to establish a state-of-the-art injectables manufacturing facility in Genome Valley, Hyderabad. The company will also employ 1,000 people from Telangana. The facility will focus on the development and production of high-quality injectable drugs in the oncology and critical care sectors, catering to both domestic and international markets.
Vivint Pharma, a leading injectables pharmaceutical company, has announced a significant investment of Rs 400 crore to establish a state-of-the-art injectables manufacturing facility in Genome Valley, Hyderabad. The company will also employ 1,000 people from Telangana. The facility will focus on the development and production of high-quality injectable drugs in the oncology and critical care sectors, catering to both domestic and international markets.
Furthermore, the company will establish its first manufacturing plant, having acquired 5.5 acres in Genome Valley. This strategic investment aligns with Vivint Pharma’s goal to leverage India’s skilled workforce and the region’s advanced manufacturing capabilities to meet the growing global demand for pharmaceutical products.
“This investment is a testament to the business-friendly environment nurtured by our Government. Genome Valley continues to be a magnet for pharmaceutical companies, and Vivint Pharma’s decision to set up a new manufacturing facility here reaffirms our leadership in the life sciences domain,” said state IT minister D. Sridhar Babu.
Vivint Pharma, a leading injectables pharmaceutical company, has announced a significant investment of Rs 400 crore to establish a state-of-the-art injectables manufacturing facility in Genome Valley, Hyderabad. The company will also employ 1,000 people from Telangana. The facility will focus on the development and production of high-quality injectable drugs in the oncology and critical care sectors, catering to both domestic and international markets.
Furthermore, the company will establish its first manufacturing plant, having acquired 5.5 acres in Genome Valley. This strategic investment aligns with Vivint Pharma’s goal to leverage India’s skilled workforce and the region’s advanced manufacturing capabilities to meet the growing global demand for pharmaceutical products.
“This investment is a testament to the business-friendly environment nurtured by our Government. Genome Valley continues to be a magnet for pharmaceutical companies, and Vivint Pharma’s decision to set up a new manufacturing facility here reaffirms our leadership in the life sciences domain,” said state IT minister D. Sridhar Babu.
Other investments and job opportunities in Hyderabad have been announced recently. Arcesium, a leading provider of technology and service solutions for asset managers, has expanded its Hyderabad facility, planning to employ 500 high-end tech professionals over the next two years. Trigyn Technologies, an IT service management company, has signed an agreement with the Telangana government to establish an AI innovation and delivery centre in Hyderabad, providing jobs and training for at least 1,000 IT role aspirants in the state. Additionally, on August 4, Cognizant announced its expansion plans in Hyderabad with a new facility spanning one million square feet, expected to create 15,000 new jobs. This agreement was solidified during the state government’s delegation visit to Davos earlier this year, led by the chief minister.
